Salicyn 30 - Sorrento Therapeutics
Alternative Names: Salicyn-30; STI-2030Latest Information Update: 16 Oct 2020
At a glance
- Originator Sorrento Therapeutics
- Class Anilides; Antivirals; Salicylates; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 08 Oct 2020 Preclinical pharmacodynamic data released by Sorrento Therapeutics
- 08 Oct 2020 Sorrento Therapeutics plans clinical trials of orally administered Salicyn 30 (Monotherapy, Combination therapy)
- 04 Oct 2020 Salicyn 30 is available for licensing as of 04 Oct 2020. https://sorrentotherapeutics.com/partnership/